(VIANEWS) – AMSC (AMSC.OL), BW LPG (BWLPG.OL), ORKLA (ORK.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. AMSC (AMSC.OL)
1395% sales growth and 8.21% return on equity
AMSC ASA, through its subsidiaries, operates as a ship owning and lease finance company in the United States. The company purchases and bareboat charters out vessels to operators and end users. It operates a fleet of nine product tankers, one shuttle tanker, and one subsea construction vessel. The company was formerly known as American Shipping Company ASA and changed its name to AMSC ASA in October 2022. AMSC ASA was founded in 2005 and is headquartered in Lysaker, Norway.
Earnings Per Share
As for profitability, AMSC has a trailing twelve months EPS of kr4.3.
PE Ratio
AMSC has a trailing twelve months price to earnings ratio of 6.51. Meaning, the purchaser of the share is investing kr6.51 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.21%.
More news about AMSC.
2. BW LPG (BWLPG.OL)
31.1% sales growth and 20.16% return on equity
BW LPG Limited, an investment holding company, engages in shipowning and chartering activities worldwide. The company operates through Shipping and Product Services segments. It is involved in the transportation of liquefied petroleum gas to oil companies, and trading and utility companies. The company also offers integrated liquified petroleum gas (LPG) delivery services directly to buyers and receivers. It owns and operates LPG vessels and a fleet of very large gas carriers. The company was formerly known as BW Gas LPG Holding Limited and changed its name to BW LPG Limited in September 2013. BW LPG Limited was founded in 1935 and is headquartered in Singapore.
Earnings Per Share
As for profitability, BW LPG has a trailing twelve months EPS of kr32.17.
PE Ratio
BW LPG has a trailing twelve months price to earnings ratio of 4.27. Meaning, the purchaser of the share is investing kr4.27 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.16%.
More news about BW LPG.
3. ORKLA (ORK.OL)
17.8% sales growth and 12.71% return on equity
Orkla ASA engages in branded consumer goods, and industrial and financial investment businesses. The company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. It also provides confectionery, biscuit, and snack products; and develops bran and crispbread products, as well as energy snack meals. In addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic and wool garments for men, women, and children; and professional cleaning products. Further, it operates Gymgrossisten, Proteinfabrikken, Bodystore, and Fitnessmarket e-commerce portals for health and sports nutrition products; and restaurants. Additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the Nordic power market; and develops and sells real estate properties. It offers its food products under the Grandiosa, TORO, Stabburet, Felix, Paulúns, NATURLI', Abba, Beauvais, Den Gamle Fabrik, Spilva, and Vitana brands; confectionery and snacks under the KiMs, Nidar, Stratos, Sætre, Göteborgs Kex, OLW, Panda, Laima, Selga, Taffel, Kalev, and Nói Síríus brands; health and sports nutrition under e Zalo, Jif, Bliw, Grumme, Blenda, Define, Möller's, Collett, Nutrilett, Maxim, Norgesplaster, and Salvequick brands; and food ingredients under the Odense, Mors Hjemmebakte, KronJäst, Bakkedal, and NATURLI brands. It has operations in Norway, Sweden, Denmark, Finland, Iceland, the Baltics, rest of Europe, and internationally. The company was founded in 1918 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ORKLA has a trailing twelve months EPS of kr5.37.
PE Ratio
ORKLA has a trailing twelve months price to earnings ratio of 15.47. Meaning, the purchaser of the share is investing kr15.47 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.71%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ORKLA’s EBITDA is 34.13.
Yearly Top and Bottom Value
ORKLA’s stock is valued at kr83.06 at 16:20 EST, below its 52-week high of kr84.54 and way higher than its 52-week low of kr67.66.
Volume
Today’s last reported volume for ORKLA is 105253 which is 88.19% below its average volume of 891373.
Sales Growth
ORKLA’s sales growth is 9.6% for the ongoing quarter and 17.8% for the next.
More news about ORKLA.
4. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 16.03% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23. Meaning, the purchaser of the share is investing kr23 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the present quarter and 6.6% for the next.
Moving Average
VISTIN PHARMA’s value is higher than its 50-day moving average of kr22.60 and above its 200-day moving average of kr22.54.
More news about VISTIN PHARMA.
